NUMD: AI 评分 49/100 — AI 分析 (4月 2026)

Nu-Med Plus, Inc. is a medical device company focused on developing and commercializing nitric oxide delivery systems. The company targets hospitals, health systems, and the medical community, offering solutions for clinical and research applications.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Nu-Med Plus, Inc. is a medical device company specializing in nitric oxide delivery systems for hospitals, health systems, and research applications. With a focus on innovation and commercialization, the company operates in a competitive landscape of medical device manufacturers, facing challenges in market penetration and financial sustainability.

NUMD是做什么的？

Nu-Med Plus, Inc., incorporated in 2011 and headquartered in Salt Lake City, Utah, is a medical device company engaged in the design, development, enhancement, and commercialization of medical devices globally. The company focuses on nitric oxide delivery systems, offering a range of products including a hospital nitric oxide delivery system, a clinical nitric oxide delivery system, a mobile rechargeable device for nitric oxide gas delivery, and a nitric oxide system for research applications. These systems are designed to serve hospitals, health systems, and the broader medical community. Nu-Med Plus aims to improve patient care through innovative nitric oxide delivery solutions. However, as a small company with only two employees, it faces significant challenges in scaling its operations, securing funding, and competing with larger, more established players in the medical device industry. The company's success hinges on its ability to navigate regulatory hurdles, establish strategic partnerships, and effectively commercialize its products.

NUMD的投资论点是什么？

Investing in Nu-Med Plus, Inc. presents a high-risk, high-reward scenario. The company's focus on nitric oxide delivery systems addresses a specific need within the medical community, potentially offering significant growth opportunities. However, with a market capitalization of $0.00B and a negative P/E ratio of -16.98, the company's financial stability is a major concern. The negative beta of -3.24 suggests an inverse correlation with the market, which could be attractive during economic downturns but also indicates unique company-specific risks. The company's future hinges on successful product commercialization and securing additional funding. Investors should carefully weigh the potential benefits against the substantial risks before considering an investment in NUMD.

NUMD在哪个行业运营？

Nu-Med Plus, Inc. operates within the medical device industry, a sector characterized by rapid innovation, stringent regulatory requirements, and intense competition. The global medical device market is projected to reach trillions of dollars by 2026, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. Nu-Med Plus competes with established medical device manufacturers like BNVIF, CRYM, CSSI, KLYG, and MSIU, as well as smaller, specialized firms. The company's success depends on its ability to differentiate its nitric oxide delivery systems, navigate regulatory pathways, and secure market share in a crowded landscape.

Medical - Devices

Healthcare

NUMD有哪些增长机遇？

Expansion into Emerging Markets: Nu-Med Plus, Inc. can pursue growth by expanding its market reach into emerging economies where healthcare infrastructure is developing and demand for advanced medical devices is increasing. The global market for medical devices in emerging economies is projected to grow at a CAGR of 8-10% over the next five years, offering a significant opportunity for NUMD to increase its revenue and market share. Success hinges on navigating regulatory hurdles and establishing strategic partnerships in these regions.
Strategic Partnerships with Hospitals and Health Systems: Collaborating with hospitals and health systems can provide Nu-Med Plus, Inc. with access to established distribution channels and a broader customer base. By partnering with key healthcare providers, NUMD can integrate its nitric oxide delivery systems into existing treatment protocols and gain valuable market validation. The timeline for establishing these partnerships is estimated at 1-2 years, with potential revenue impact within 2-3 years of implementation.
Development of New Nitric Oxide Delivery Applications: Nu-Med Plus, Inc. can invest in research and development to expand the applications of its nitric oxide delivery systems beyond current uses. Exploring new therapeutic areas, such as pulmonary hypertension, wound healing, and cardiovascular diseases, can open up new market segments and drive revenue growth. The R&D timeline is estimated at 2-3 years, with potential commercialization within 3-5 years.
Securing Regulatory Approvals for New Products: Obtaining regulatory approvals from agencies like the FDA is crucial for Nu-Med Plus, Inc. to commercialize its products and gain market access. Successfully navigating the regulatory process for new nitric oxide delivery systems can provide a significant competitive advantage and drive revenue growth. The regulatory approval process typically takes 1-3 years, depending on the complexity of the device and the clinical data required.
Acquisition or Merger with a Larger Medical Device Company: Nu-Med Plus, Inc. could explore strategic opportunities such as an acquisition or merger with a larger medical device company to gain access to additional resources, expertise, and distribution channels. This could accelerate the company's growth and enhance its market position. The timeline for such a transaction is highly variable, but could potentially be completed within 1-2 years.

Market Cap of $0.00B indicates a micro-cap company with limited resources and high volatility.
P/E Ratio of -16.98 reflects negative earnings, suggesting the company is not currently profitable.
Profit Margin of -9019.8% highlights significant operational inefficiencies and substantial losses.
Gross Margin of 50.0% indicates potential profitability at the product level, but high operating expenses erode overall profitability.
Beta of -3.24 suggests the stock is inversely correlated with the market, offering potential diversification benefits but also indicating company-specific risks.

NUMD提供哪些产品和服务？

Designs and develops medical devices.
Specializes in nitric oxide delivery systems.
Offers hospital nitric oxide delivery systems.
Provides clinical nitric oxide delivery systems.
Develops mobile rechargeable nitric oxide delivery devices.
Creates nitric oxide systems for research applications.

NUMD如何赚钱？

Develops and sells nitric oxide delivery systems.
Targets hospitals, health systems, and the medical community.
Generates revenue through product sales.

Hospitals
Health systems
Medical community

Proprietary nitric oxide delivery technology.
Specialized focus on a niche market.
Potential for intellectual property protection through patents.

什么因素可能推动NUMD股价上涨？

Ongoing: Development of new nitric oxide delivery applications could expand market reach.
Upcoming: Potential regulatory approvals for new products can drive revenue growth.
Ongoing: Strategic partnerships with hospitals and health systems can provide access to established distribution channels.

NUMD的主要风险是什么？

Ongoing: Intense competition from established medical device manufacturers.
Ongoing: Stringent regulatory requirements can delay or prevent product commercialization.
Potential: Limited financial resources may hinder growth and development.
Potential: Dependence on successful product commercialization increases the risk of failure.
Ongoing: The company's small size and limited resources pose challenges to its long-term viability.

NUMD的核心优势是什么？

Specialized expertise in nitric oxide delivery systems.
Potential for innovative product development.
Focus on a niche market segment.
Proprietary technology.

NUMD的劣势是什么？

Limited financial resources.
Small team size (2 employees).
Lack of established market presence.
Dependence on successful product commercialization.

NUMD有哪些机遇？

Expansion into emerging markets.
Strategic partnerships with hospitals and health systems.
Development of new nitric oxide delivery applications.
Securing regulatory approvals for new products.

NUMD面临哪些威胁？

Intense competition from established medical device manufacturers.
Stringent regulatory requirements.
Risk of product obsolescence.
Difficulty in securing funding.

NUMD的竞争对手是谁？

BioNxt Solutions Inc. — Focuses on pharmaceutical and nutraceutical products. — (BNVIF)
Cryomass Technologies Inc. — Specializes in cryogenic technologies. — (CRYM)
Cardio Systems, Inc. — Develops cardiovascular medical devices. — (CSSI)
Kaly Gene Therapeutics, Inc. — Focuses on gene therapy research and development. — (KLYG)
Medical Solutions International, Inc. — Provides medical equipment and supplies. — (MSIU)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: William R. Colvin
Headquarters: Salt Lake City, US
Employees: 2
Founded: 2014

AI Insight

AI analysis pending for NUMD

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Nu-Med Plus, Inc. do?

Nu-Med Plus, Inc. is a medical device company that specializes in the design, development, and commercialization of nitric oxide delivery systems. These systems are used in hospitals, health systems, and for research applications. The company's product line includes hospital nitric oxide delivery systems, clinical nitric oxide delivery systems, mobile rechargeable devices for nitric oxide gas delivery, and nitric oxide systems for research purposes. Nu-Med Plus aims to provide innovative solutions for delivering nitric oxide, a gas with various therapeutic applications.

What do analysts say about NUMD stock?

There is currently no available analyst coverage for Nu-Med Plus, Inc. (NUMD). Given its micro-cap status and OTC listing, the company is unlikely to be actively followed by major research firms. Investors should conduct their own due diligence and carefully consider the risks and opportunities associated with investing in NUMD before making any investment decisions. Key valuation metrics, such as revenue growth, profitability, and cash flow, should be analyzed in conjunction with the company's growth prospects and competitive landscape.

What are the main risks for NUMD?

Nu-Med Plus, Inc. faces several significant risks. As a small company with limited financial resources, it is vulnerable to competition from larger, more established medical device manufacturers. The company's success depends on its ability to successfully commercialize its products and secure regulatory approvals, which can be a lengthy and expensive process. Additionally, the company's OTC listing and lack of financial disclosure increase the risk of investing in NUMD. Investors should carefully consider these risks before investing.